The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs).
 
Patrick Schöffski
Consulting or Advisory Role - Adcendo; Amryt Pharma; Avacta Life Sciences; Boehringer Ingelheim; Boxer Capital; Cogent Biosciences; Curio Science; Deciphera; Eisai; Ellipses Pharma; Exelixis; Genmab; IDRx; LLX Solutions; Medpace; Merck; Moleculin Biotech; NEC OncoImmunity AS; NEC OncoImmunity AS; PharmaMar; Regeneron; Sanofi; SERVIER; Sonata Therapeutics; Studiecentrum voor Kernenergie (SCK CEN); Telix Pharmaceuticals; Transgene; UCB
Research Funding - Adcendo (Inst); CoBioRes NV (Inst); Eisai (Inst); G1 Therapeutics (Inst); Genmab (Inst); Merck (Inst); ONA therapeutics (Inst); PharmaMar (Inst); Sartar Therapeutics (Inst)
 
Michael C. Heinrich
Honoraria - Novartis
Consulting or Advisory Role - Cogent Pharmaceuticals; Deciphera; Novartis; Theseus Pharmaceuticals
Research Funding - Cogent Biosciences
Patents, Royalties, Other Intellectual Property - Patent on treatment of GIST-licensed to Novartis (Inst)
 
Jonathan C. Trent
Consulting or Advisory Role - AADi; Agios; Bayer; Blueprint Medicines; Boehringer Ingelheim; C4 Therapeutics; Cogent Medicine; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; SERVIER
 
Cesar Serrano
Honoraria - Deciphera; PharmaMar; Roche
Consulting or Advisory Role - Blueprint Medicines; Cogent Biosciences; Deciphera; IDRX; Immunicum; NewBay Pharma
Research Funding - IDRX (Inst); Karyopharm Therapeutics (Inst)
Travel, Accommodations, Expenses - Bayer; Gilead Sciences; Pfizer; PharmaMar
 
Sebastian Bauer
Honoraria - Deciphera; GlaxoSmithKline; Novartis; Pharmamar
Consulting or Advisory Role - ADC Therapeutics; Adcendo; Bayer; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; Exelixis; GlaxoSmithKline; IDRX; Janssen-Cilag; Lilly; Mundipharma; Nanobiotix
Research Funding - Blueprint Medicines; Incyte (Inst); Novartis
Travel, Accommodations, Expenses - Pharmamar
 
Margaret von Mehren
Honoraria - Boehringer Ingelheim; Deciphera; Molleculin
Consulting or Advisory Role - deciphera
Research Funding - ASCO (Inst); Deciphera (Inst); IDRx (Inst); Novartis (Inst); Solaris Health (Inst); Sumitomo Pharma Oncology (Inst); Theseus (Inst)
Patents, Royalties, Other Intellectual Property - cell line
Travel, Accommodations, Expenses - Boehringer Ingelheim
Other Relationship - NCCN
 
Neeta Somaiah
Stock and Other Ownership Interests - JNJ (I); Pfizer (I)
Consulting or Advisory Role - AADi; Bayer; Blueprint Medicines; Boehringer Ingelheim; Deciphera; Epizyme
Research Funding - Advenc; Ascentage Pharma; AstraZeneca/MedImmune (Inst); Cogent Biosciences; Daiichi Sankyo/Lilly; Deciphera; GlaxoSmithKline; Karyopharm Therapeutics
 
Peter Reichardt
Honoraria - Boehringer Ingelheim (Inst); Clinigen Group (Inst); Deciphera (Inst); PharmaMar (Inst)
Consulting or Advisory Role - Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Mundipharma (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst)
Research Funding - Novartis (Inst)
 
George D. Demetri
Leadership - Blueprint Medicines
Stock and Other Ownership Interests - AADi; Acrivon Therapeutics; Bessor Pharma; Blueprint Medicines; Boundless Bio; Caprion/HistoGeneX; Caris Life Sciences; Erasca, Inc; G1 Therapeutics; IDRx; Ikena Oncology; Kojin Therapeutics; Relay Therapeutics; Tessellate Bio
Consulting or Advisory Role - AADi; Acrivon Therapeutics; Arsenal Capital; Blueprint Medicines; Caprion/HistoGeneX; Caris Life Sciences; Daiichi Sankyo; EMD Serono; IDRx; Ikena Oncology; Jazz Pharmaceuticals; Kojin Therapeutics; Merck KGaA; Minghui Pharmaceuticals; Mirati Therapeutics; PharmaMar; Rain Therapeutics; Relay Therapeutics; Sumitomo Pharma Oncology; WIRB-Copernicus Group
Research Funding - Adaptimmune (Inst); Bayer (Inst)
 
Nick Lydon
Stock and Other Ownership Interests - IDRx
 
Jaap Verweij
Consulting or Advisory Role - Boehringer Ingelheim; Cancer Drug Development Forum; DeuterOncology; IDRx; University of Siegen, Germany
 
Vivek Kadambi
Employment - IDRx
Stock and Other Ownership Interests - IDRx
 
Jessica Christo
Employment - IDRx
Stock and Other Ownership Interests - IDRx
 
Sean Kim
Employment - IDRx
Stock and Other Ownership Interests - IDRx
 
Debbie Johnson
Employment - IDRx
Stock and Other Ownership Interests - IDRx
 
James Shao
Employment - IDRx
Stock and Other Ownership Interests - IDRx
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories
Honoraria - CStone Pharmaceuticals
Consulting or Advisory Role - Bayer; BioAtla; Blueprint Medicines; Daiichi; deciphera; Immunicum; Kayothera; Lilly; MORE Health; Research to Practice; UpToDate
Research Funding - Acrivon Therapeutics; BioAtla; Blueprint Medicines (Inst); Daiichi Sankyo RD Novare (Inst); Deciphera (Inst); Eisai (Inst); IDRx (Inst); Merck (Inst); NewBay Pharma (Inst); SpringWorks Therapeutics (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Expert Testimony - Bayer
Other Relationship - Research to Practice; WCG